Considerations for Moderna's move to get an EUA for the COVID-19 vaccine in young kids

Video

Editorial board member Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, discusses the recently release topline data, the potential timeline, and what potential stumbling blocks could be.

Editorial board member Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN, discusses the recently release topline data, the potential timeline, and what potential stumbling blocks could be.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!
Recent Videos
Thomas Crawford, MD, talks advancements for spinal muscular atrophy treatment | Image credit: Contemporary Pediatrics
Thomas Crawford, MD, discusses SMA and SAPPHIRE trial of apitegromab
John Browning, MD, reacts to the approval of ruxolitinib for atopic dermatitis in children
Related Content
Lawrence Eichenfield, MD, Rocco Serrao, MD, react to roflumilast approval for pediatric atopic dermatitis | Image credit: Contemporary Pediatrics

Lawrence Eichenfield, MD; and Rocco Serrao, MD, react to roflumilast approval for pediatric atopic dermatitis

Lawrence Eichenfield, MD;Rocco Serrao, MD
October 8th 2025
Article
FDA approves roflumilast cream 0.05% for atopic dermatitis for children 2 to 5 years | Image credit: Contemporary Pediatrics

FDA approves roflumilast cream 0.05% for atopic dermatitis for children aged 2 to 5 years

Joshua Fitch, Senior Editor
October 8th 2025
Article
September's FDA Focus: Approvals and pipeline updates in pediatrics | Image credit: Contemporary Pediatrics

September's FDA Focus: Approvals and pipeline updates in pediatrics

Joshua Fitch, Senior Editor
October 8th 2025
Article
FDA news in pediatrics: September 2025 | Image credit: Contemporary Pediatrics

FDA news in pediatrics: September 2025

Joshua Fitch, Senior Editor ;Morgan Ebert, Managing Editor
October 8th 2025
Article
5 pediatric FDA decisions to watch for in Q4 2025 | Image credit: Contemporary Pediatrics

Key pediatric FDA decisions to watch for in Q4 2025

Joshua Fitch, Senior Editor
October 8th 2025
Article
FDA approves guselkumab for children with plaque psoriasis and psoriatic arthritis | Image credit: Contemporary Pediatrics

FDA approves guselkumab for children with plaque psoriasis and psoriatic arthritis

Morgan Ebert, Managing Editor
October 8th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.